文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

Rho激酶抑制剂对脓毒症大鼠肠损伤的作用及机制

[Effect and mechanism of Rho kinase inhibitor on intestinal injury in septic rats].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论大鼠CLP脓毒症模型中,术前15分钟腹腔注射Y-27632 5 mg/kg可减轻肠损伤,机制可能涉及抑制RhoA/ROCK1/NF-κB通路。

该研究将32只雄性SD大鼠随机分为假手术组、Y-27632对照组、CLP脓毒症模型组和Y-27632预处理组,每组8只。Y-27632预处理组在CLP术前15分钟腹腔注射Y-27632溶液5 mg/kg。术后24小时检测显示,与CLP组相比,Y+CLP组Chiu's评分显著降低(2.85±0.21 vs. 3.83±0.27,P<0.05),肠组织ROCK1、NF-κB表达及血清DAO、肠匀浆TNF-α均显著降低,IL-10显著升高(均P<0.05)。作者认为Y-27632对脓毒症肠损伤的保护作用可能与调控RhoA/ROCK1/NF-κB信号通路有关。

要点

  • 在CLP脓毒症大鼠中,术前15分钟腹腔注射Y-27632 5 mg/kg可降低肠组织Chiu's评分(2.85±0.21 vs. 3.83±0.27,P<0.05)。
  • Y+CLP组较CLP组肠组织ROCK1表达降低[0.15(0.13,0.18)vs. 0.19(0.18,0.22),P<0.05],NF-κB表达降低(0.28±0.01 vs. 0.40±0.02,P<0.05)。
  • Y+CLP组较CLP组血清DAO降低(243.34±19.76 ng/L vs. 287.81±23.31 ng/L,P<0.05),肠匀浆TNF-α降低(90.41±8.79 ng/L vs. 101.08±5.62 ng/L,P<0.05)。
  • Y+CLP组较CLP组肠匀浆IL-10升高(66.15±5.74 μg/L vs. 55.16±5.20 μg/L,P<0.05)。
  • 作者认为Y-27632的保护作用可能与抑制RhoA/ROCK1/NF-κB信号通路、减轻肠道炎症有关。

适用人群与场景

  • 雄性Sprague-Dawley(SD)大鼠,采用盲肠结扎穿孔(CLP)复制脓毒症模型。
  • 假手术组和Y+Sham组仅分离并移动盲肠,不结扎穿孔。

诊断标准与关键阈值

  • 脓毒症肠损伤模型:CLP术后24小时肠黏膜排列紊乱、大量炎细胞浸润,Chiu's评分较假手术组显著升高(3.83±0.27 vs. 0.12±0.11,P<0.05)。

处置流程与药物剂量

  • Y+Sham组和Y+CLP组于术前15分钟腹腔注射Y-27632溶液5 mg/kg。
  • Sham组和CLP组于术前15分钟腹腔注射等量磷酸盐缓冲液(PBS)。
  • 术后24小时取心脏血,酶联免疫吸附试验(ELISA)检测血清二胺氧化酶(DAO)含量。
  • 取小肠组织,苏木素-伊红(HE)染色后光镜下观察病理改变并行Chiu's评分,免疫组化检测ROCK1和NF-κB阳性表达,ELISA检测肠组织匀浆TNF-α和IL-10水平。

研究设计与关键结果

  • 研究类型:动物实验;样本量:32只雄性SD大鼠,随机分为4组,每组8只。
  • 与Sham组比较,CLP组肠黏膜排列紊乱、大量炎细胞浸润,Chiu's评分显著升高(3.83±0.27 vs. 0.12±0.11,P<0.05),提示脓毒症肠损伤。
  • 与CLP组比较,Y+CLP组肠上皮细胞坏死程度减轻、少量炎细胞浸润,Chiu's评分显著降低(2.85±0.21 vs. 3.83±0.27,P<0.05)。
  • 与Sham组比较,CLP组肠组织ROCK1表达[0.19(0.18,0.22)vs. 0.10(0.09,0.11)]、NF-κB表达(0.40±0.02 vs. 0.15±0.01)、血清DAO(287.81±23.31 ng/L vs. 144.92±17.72 ng/L)、肠匀浆TNF-α(101.08±5.62 ng/L vs. 74.81±5.56 ng/L)均显著升高(均P<0.05),肠匀浆IL-10显著降低(55.16±5.20 μg/L vs. 95.95±7.53 μg/L,P<0.05)。
  • 与CLP组比较,Y+CLP组肠组织ROCK1表达[0.15(0.13,0.18)vs. 0.19(0.18,0.22)]、NF-κB表达(0.28±0.01 vs. 0.40±0.02)、血清DAO(243.34±19.76 ng/L vs. 287.81±23.31 ng/L)、肠匀浆TNF-α(90.41±8.79 ng/L vs. 101.08±5.62 ng/L)均显著降低(均P<0.05),肠匀浆IL-10显著升高(66.15±5.74 μg/L vs. 55.16±5.20 μg/L,P<0.05)。
  • 作者认为Y-27632预处理对脓毒症肠损伤大鼠的保护作用可能与调控RhoA/ROCK1/NF-κB信号通路有关。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠CLP脓毒症模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the effect of Rho kinase inhibitor on intestinal injury in septic rats and its possible mechanism.

METHODS: Thirty-two male Sprague-Dawley (SD) rats were randomly divided into sham operation group (Sham group), Rho kinase inhibitor Y-27632 control group (Y+Sham group), sepsis model group [cecal ligation and puncture (CLP) group] and Y-27632 pretreatment group (Y+CLP group), with 8 rats in each group. Rat sepsis model was reproduced by CLP. The rats in the Sham group and Y+Sham group were only separated and moved the cecum without ligation and perforation. The rats in the Y+Sham group and Y+CLP group were pretreated with intraperitoneal injection of Y-27632 solution 5 mg/kg 15 minutes before operation; the rats in the Sham group and CLP group were intraperitoneally injected with the same amount of phosphate buffered saline (PBS). Twenty-four hours after operation, the heart blood was collected and the serum diamine oxidase (DAO) content was determined by enzyme-linked immunosorbent assay (ELISA). Then the small intestine tissue was collected, the pathological changes of the intestinal tissue were observed under the light microscope after hematoxylin-eosin (HE) staining, and Chiu's score was performed. The positive expressions of Rho-related coiled-coil kinase 1 (ROCK1) and nuclear factor-κB (NF-κB) in intestinal tissue were detected by immunohistochemistry. ELISA was used to detect the levels of tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) in intestinal tissue homogenate.

RESULTS: The intestinal tissue structure of the Sham group and Y+Sham group was intact and the mucosa was arranged neatly. Compared with the Sham group, the intestinal mucosa of the CLP group was arranged disorderly, with a large number of inflammatory cells infiltration, and the Chiu's score was significantly increased (3.83±0.27 vs. 0.12±0.11, P < 0.05), indicating that those rats suffered from septic intestinal injury. Compared with the CLP group, the degree of necrosis of intestinal epithelial cells in the Y+CLP group was reduced, a small amount of inflammatory cells infiltration was seen, and the Chiu's score was significantly decreased (2.85±0.21 vs. 3.83±0.27, P < 0.05), indicating that Y-27632 pretreatment could alleviate intestinal injury in septic rats. Compared with the Sham group, the positive expressions of intestinal tissue ROCK1 and NF-κB, the contents of serum DAO and intestinal homogenate TNF-α in the CLP group were significantly increased [ROCK1 expression (A value): 0.19 (0.18, 0.22) vs. 0.10 (0.09, 0.11), NF-κB expression (A value): 0.40±0.02 vs. 0.15±0.01, DAO (ng/L): 287.81±23.31 vs. 144.92±17.72, TNF-α (ng/L): 101.08±5.62 vs. 74.81±5.56, all P < 0.05], the level of intestinal homogenate IL-10 was significantly decreased (μg/L: 55.16±5.20 vs. 95.95±7.53, P < 0.05). Compared with the CLP group, the positive expressions of intestinal tissue ROCK1, NF-κB, the contents of serum DAO and intestinal homogenate TNF-α in the Y+CLP group were significantly decreased [ROCK1 expression (A value): 0.15 (0.13, 0.18) vs. 0.19 (0.18, 0.22), NF-κB expression (A value): 0.28±0.01 vs. 0.40±0.02, DAO (ng/L): 243.34±19.76 vs. 287.81±23.31, TNF-α (ng/L): 90.41±8.79 vs. 101.08±5.62, all P < 0.05], while the level of intestinal homogenate IL-10 was significantly increased (μg/L: 66.15±5.74 vs. 55.16±5.20, P < 0.05), indicating that the protective effect of Y-27632 pretreatment on sepsis intestinal injury rats might be related to the regulation of RhoA/ROCK1/NF-κB signaling pathway.

CONCLUSIONS: Rho kinase inhibitors can reduce intestinal injury in septic rats, and the mechanism may be related to inhibiting RhoA/ROCK1/NF-κB signaling pathway and reducing intestinal inflammation in septic rats.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Ning H, Guo N, Xing B, et al. [Effect and mechanism of Rho kinase inhibitor on intestinal injury in septic rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36567581. doi:10.3760/cma.j.cn121430-20210923-01392

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。